Laryngeal cancer stage III Trials in Disease

Study of low-dose radiation therapy combined with paclitaxel and carboplatin in patients with advanced throat and larynx cancer

This trial is testing a treatment approach that combines low-dose radiation therapy with two chemotherapy drugs: paclitaxel and carboplatin. Both medications are given through an intravenous line directly into the bloodstream. The study aims to find out how well this combined treatment works for patients with advanced throat and larynx cancer and how well patients tolerate it.

Who can participate:

• Adults between 18 and 65 years old
• People with advanced cancer of the throat or voice box that has not been treated before
• Patients whose cancer has spread to lymph nodes in the neck (larger than 2 cm or at stages N2 or N3) but has not spread to distant parts of the body
• Individuals who are healthy enough to receive chemotherapy treatment
• Both men and women can take part

Who cannot participate:

• People younger than 18 or older than 65 years
• Patients whose cancer has spread to other parts of the body
• Those who have previously received radiation therapy to the head and neck area
• People with serious heart problems, severe kidney or liver disease, or uncontrolled diabetes
• Pregnant or breastfeeding women
• Individuals with active infections, weakened immune systems, or autoimmune diseases
• Those with known allergies to the study medications
• People with mental conditions that prevent them from understanding the trial requirements or those with active substance abuse problems

What the trial involves:

The treatment consists of a combination therapy called induction radiochemotherapy. This means patients receive both radiation therapy and chemotherapy at the start of their treatment. The radiation is given at lower doses than traditional approaches, and the two chemotherapy drugs work together with the radiation to help destroy cancer cells more effectively.

During the trial, which lasts up to 37 days for the active treatment phase, doctors will carefully monitor how the cancer responds to treatment. They will check the treated area and lymph nodes regularly, watch for any side effects, and track whether the cancer has spread. Follow-up monitoring will continue until December 2028 to see how long patients remain cancer-free and to detect any potential return of the disease early.

The study also examines how low doses of radiation affect the body at molecular and biochemical levels, helping researchers better understand this treatment approach.